7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indole

a PET imaging agent selective for paired helical filaments of tau protein

Also Known As:

(18)AV-1451; (18)F-flortaucipir; (18F)1451; (18F)AV-1451; (18F)T807 compound; (18F)flortaucipir; (F-18)-AV-1451; (F-18)T807; AV-1451; AV1451; F-18-AV-1451; T-807; T-807 F-18; T807 compound; flortaucipir; flortaucipir (18F); flortaucipir (F 18); flortaucipir (F-18)

Networked: 191 relevant articles (2 outcomes, 35 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Carbolines: 283
      - 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole: 191
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Carbolines: 283
        7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole: 191
  - 3-Ring Heterocyclic Compounds
    - Carbolines: 283
      - 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole: 191

Experts

1.	Ossenkoppele, Rik: 25 articles (01/2022 - 02/2017)
2.	Jack, Clifford R: 23 articles (11/2022 - 01/2016)
3.	Lowe, Val J: 23 articles (11/2022 - 01/2016)
4.	Petersen, Ronald C: 19 articles (11/2022 - 01/2016)
5.	Knopman, David S: 18 articles (11/2022 - 01/2016)
6.	Schwarz, Christopher G: 18 articles (11/2022 - 01/2017)
7.	Senjem, Matthew L: 16 articles (11/2022 - 01/2017)
8.	Devous, Michael D: 16 articles (01/2021 - 03/2017)
9.	Alzheimer’s Disease Neuroimaging Initiative: 15 articles (01/2022 - 01/2019)
10.	Hansson, Oskar: 15 articles (01/2022 - 08/2017)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/2023 - "Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [18F]flortaucipir study." 01/01/2021 - "In this combined positron emission tomography (PET) and magnetoencephalography (MEG) study, we aimed to investigate spatial associations between regional tau pathology ([18F]flortaucipir PET), synaptic density (synaptic vesicle 2A [11C]UCB-J PET) and synaptic function (MEG) in Alzheimer's disease. " 06/15/2020 - "Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study." 11/07/2023 - "Recently, the US Food and Drug Administration approved the tau-binding radiotracer [18F]flortaucipir and an accompanying visual read method to support the diagnostic process in cognitively impaired patients assessed for Alzheimer disease (AD). " 01/01/2023 - "Several [18F]Flortaucipir cutoffs have been proposed for tau PET positivity (T+) in Alzheimer's disease (AD), but none were data-driven. "
2.	Disease Progression 01/01/2023 - "Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression." 01/01/2021 - "To evaluate the association between flortaucipir PET visual interpretation and patients' near-term clinical progression. " 01/01/2022 - "Among the flortaucipir indices, the machine-learning derived SPARE-Tau index was the most sensitive clinical progression biomarker. " 01/01/2022 - "Beyond the AJR: "Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials"." 01/01/2021 - "Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials."
3.	Frontotemporal Dementia (Semantic Dementia) 01/01/2020 - "Longitudinal (18F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation." 01/01/2020 - "To assess volume loss and flortaucipir uptake in patients with semantic dementia (SD) over time. " 01/01/2020 - "Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia." 01/01/2020 - "In vitro autoradiography showed no [18F]AV1451 binding in SV PPA due to FTLD-TDP, while specific binding was present in SV PPA due to AD and PiD. " 01/01/2020 - "Absence of specific [18F]AV1451 binding was observed for all three SV PPA FTLD-TDP cases. "
4.	Cognitive Dysfunction 01/01/2018 - "Methods: Twenty-one subjects who completed the study (5 healthy controls, 6 mild cognitive impairment, and 10 AD) received 370 MBq of flortaucipir F 18 and were imaged for 20 min beginning 80 min after injection and again at 110 min after injection. " 01/01/2022 - "SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline." 01/01/2022 - "The bridging integrator 1(BIN1) rs744373 risk polymorphism has been linked to increased [18F]AV1451 signal in non-demented older adults (ie., mild cognitive impairment [MCI] plus cognitively normal [CN] individuals). " 01/01/2021 - "Noteworthy, discordant participants with normal PET exhibited reduced flortaucipir uptake in Braak stage ROIs and slower rates of cognitive decline, relative to those PET-positive. " 01/01/2021 - "Cognitive impairment was associated with increased flortaucipir uptake in regionally specific patterns consistent with the neuroanatomy underlying specific cognitive tests. "
5.	Tauopathies 01/01/2023 - "The purpose of this study is to determine how flortaucipir uptake links to neuropathologically determined tau burden in AD and non-AD tauopathies. " 01/01/2021 - "Our computational study reveals that different affinity binding sites exist for AV-1451 in the tau fibrils associated with different tauopathies. " 01/01/2021 - "In the present study, we have performed a multiscale computational study involving molecular docking, molecular dynamics, free energy calculations, and QM fragmentation calculations to understand the binding profiles of tau tracer AV-1451 and its potential use for diagnosis of AD, CTE, and PiD tauopathies. " 01/01/2021 - "Automated production of [18F]Flortaucipir for PET imaging of tauopathies." 01/01/2021 - "Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy."

Related Drugs and Biologics

1.	florbetapir
2.	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)
3.	Amyloid (Amyloid Fibrils)
4.	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indole
5.	Biomarkers (Surrogate Marker)
6.	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)
7.	Ligands
8.	THK5351
9.	Carbon
10.	Glycoproteins (Glycoprotein)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Aftercare (After-Treatment)